Secukinumab (anti-IL-17A) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-17A, >95%, Human IgG1, INHIBITOR of Interleukin 17A inhibitor, INHIBITOR of Interleukin 17A inhibitor

CAS: 1229022-83-6 Cat. No.: S412013

GRADE & PURITY Animal Free, Carrier Free, Recombinant, Validated, ExactAb™, Low Endotoxin, Azide Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Application

Animal Model, ELISA, Flow Cytometry, Functional Assay

Host species

Human

Reactive species

Cynomolgus monkey, Human, Rhesus monkey

Isotype

Human IgG1

Conjugation

Unconjugated

Overview

Secukinumab (anti-IL-17A) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. Secukinumab (anti-IL-17A) is the first-in-class anti-IL-17 agent used for the research of plaque psoriasis, ankylosing spondylitis and psoriatic arthritis.

Specifications

Product Name

Secukinumab (anti-IL-17A) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to IL-17A, >95%, Human IgG1, INHIBITOR of Interleukin 17A inhibitor

Synonyms

CTLA-8 | Cytotoxic T-lymphocyte-associated antigen 8 | IL-17 | IL-17A

Specifications & Purity

Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Biochemical and Physiological Mechanisms

Induces stromal cells to produce proinflammatory and hematopoietic cytokines. Enhances the surface expression of the intracellular adhesion molecule-1 (ICAM-1) in fibroblasts.

Host species

Human

Specificity

IL-17A

Application

ELISA, Functional Assay, Flow cytometry, Kinetics (BLI), Kinetics (SPR)

Conjugation

Unconjugated

Grade

Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated

Action Type

INHIBITOR

Mechanism of action

INHIBITOR of Interleukin 17A inhibitor

Antibody Type

Primary antibody

Clonality

Recombinant

Isotype

Human IgG1

Light Chain Type

kappa

SDS-PAGE

26.6 kDa (Light Chain) & 51.9 kDa (Heavy Chain), under reducing conditions; 180.9 kDa, under non-reducing conditions.

Purification Method

Protein A purified

Purity

>95%

Source

CHO supernatant

Concentration

See COA

CAS

1229022-83-6

Storage and Shipping

Shape

Liquid

Storage

Store at -80°C,Avoid repeated freezing and thawing

Shipped In

Dry ice packs + Cold packs

Stability And Storage

Store at -80℃ long term (24 months). Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Images

ELISA: Secukinumab (anti-IL-17A) (S412013)

Secukinumab (anti-IL-17A) (S412013) - ELISA
Immobilized Recombinant Human IL-17A Protein at 1 μg/mL can bind Secukinumab (anti-IL-17A) (S412013) with the EC50 of 69.38 ng/mL.

SEC: Secukinumab (anti-IL-17A) (S412013)

Secukinumab (anti-IL-17A) (S412013) - SEC
The purity of Secukinumab (anti-IL-17A) (S412013) is more than 95% verified by HPLC.

Associated Targets(Human)

IL17A Tclin Interleukin-17A (0 Activities)

Discover Target: IL17A

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mechanisms of Action

References

1. Chenmei Peng, Pan Lei, Hongying Qi, Qianjun Zhu, Chushun Huang, Ju Fu, Chengyu Zhao.  (2025)  Effect of fecal microbiota transplantation on diabetic wound healing through the IL-17A–mTOR–HIF1α signaling axis.  APPLIED AND ENVIRONMENTAL MICROBIOLOGY,      [PMID:40019272] [10.1128/aem.02019-24]